YES NO UNKNOWN. Stage I: Rule-Out Dashboard ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES ( 1 of above)
|
|
- Octavia Johnston
- 5 years ago
- Views:
Transcription
1 Stage I: Rule-Out Dashboard GENE/GENE PANEL: ENG, ACVRL1, SMAD4, GDF2 DISORDER: Hereditary Hemorrhagic Telangiectasia HGNC ID: 3349, 175, 6770, 4217 OMIM ID: , , , ACTIONABILITY PENETRANCE 1. Is there a qualifying resource, such as a practice guideline or systematic review, for the genetic condition? YES NO 2. Does the practice guideline or systematic review indicate that the result is actionable in one or more of the following ways? 4. Is there at least one known pathogenic variant with at least moderate penetrance ( 40%) or moderate relative risk ( 2) in any population? YES NO UNKNOWN SIGNIFICANCE/BURDEN OF DISEASE Yes No Patient Management Surveillance or Screening 5. Is this condition an important health problem? YES NO Family Management NEXT STEPS Circumstances to Avoid YES ( 1 of above) NO 3. Is the result actionable in an undiagnosed adult with the genetic condition? YES NO 6. Are Actionability (Q2-3), Penetrance (Q4), and Significance (Q5) all YES? YES (Proceed to Stage II) NO (Consult Actionability Working Group) Exception granted, proceed to Stage II Exception not granted, STOP 1
2 GENE/GENE PANEL: ENG, ACVRL1, SMAD4, GDF2 DISORDER: Hereditary Hemorrhagic Telangiectasia Topic Narrative Description of Evidence Ref Signif/Burden of Condition 1. What is the nature of the threat to health for an individual carrying a deleterious allele? Prevalence of the genetic disorder Clinical Features (Signs/symptoms) Natural History (Important subgroups & survival/recovery) The estimated prevalence of hereditary hemorrhagic telangiectasia (HHT) ranges from 1/10,000 to 1/5000. HHT is characterized by the presence of multiple arteriovenous malformations (AVMs) that lack intervening capillaries and result in direct connections between arteries and veins. Small telangiectases close to the surface of the skin and mucous membranes often rupture and bleed after slight trauma and are most evident on the lips, tongue, buccal mucosa, face, chest and fingers. They are common in adulthood throughout the gastrointestinal mucosa. Recurrent and spontaneous epistaxis (nosebleed) is the most common symptom of HHT and is the most common feature to bring young individuals with HHT to medical attention. It is caused by minor insults from drying air and repeated minor abrasions to the fragile nasal mucosa. Epistasis and/or GI bleeding can cause mild to severe anemia, often requiring iron replacement therapy or blood transfusion. HHT is often complicated by the presence of AVMs in the brain, lung, gastrointestinal tract, and liver. In contrast to complications of smaller telangiectases, the complications of AVMs often result from the shunting of blood, leading to increased cardiac output and, in the lung, desaturation of arterial blood. Patients with mutations in the SMAD4 genes may also be affected by a rare syndrome that combines HHT and juvenile polyposis. Although HHT is a developmental disorder and infants are occasionally severely affected, in most people the features are age-dependent and the diagnosis is not suspected until adolescence or later. The average age of onset for epistaxis is 12 years, with 50-80% of patients affected before the age of 20 and 78-96% developing it eventually. Most patients report the appearance of telangiectasia of the mouth, face, or hands 5-30 years after the onset of nose bleeds, most commonly during the third decade. GI bleeding, when present, usually presents in the 5 th or 6 th decades of life. Patients rarely develop significant GI bleeding before 40 years of age. Women are affected with GI bleeding in a ratio of 2-3:1. AVMs of the brain are typically present at birth, whereas those in the lung and liver typically develop over time. Hemorrhage is often the presenting symptom of cerebral AVMs, while visceral AVMs may cause transient ischemic attacks, embolic stroke, and cerebral or other abscesses. Hepatic AVMs can present as high-output heart failure, portal hypertension, or biliary disease. 2. How effective are interventions for preventing the harm? Information on the effectiveness of the recommendations below was not provided unless otherwise stated. To establish the extent of disease and needs in an individual diagnosed with HHT the following evaluations are recommended: Medical history and physical exam Complete blood count Measurement of oxygen saturation via pulse oximetry Contrast echocardiography for detection of pulmonary shunting/avm and measurement of the pulmonary artery systolic pressure as a screen for pulmonary Patient artery hypertension (Tier 3) Management Patients with HHT-related epistaxis should use agents that humidify the nasal mucosa to prevent endonasal crusting that can damage endonasal telangiectasia and cause bleeding. There are small case series of various topical medications, including lubricants (e.g., saline, antibiotic ointments), as well as topical estrogen cream/ointment and antifibrinolytics, with variable success in decreasing HHT-related epistaxis. There are insufficient published data to recommend one topical therapy over another; however, expert experience is that there is (1, 2) (1, 2) (1, 2) 2
3 mild benefit from humidification and that the risk of topical lubricants and saline is very low. (Tier 2) Surveillance When considering nasal surgery for reasons other than epistaxis the patients and the clinician should obtain consultation from an otorhinolaryngologists with expertise in HHTrelated epistaxis who can guide procedural interventions to minimize risk of worsening epistaxis. (Tier 2) Patients should undergo annual evaluation by a health care provider familiar with HHT, including interval history for epistaxis or other bleeding, shortness of breath or decreased exercise tolerance, and headache or other neurologic symptoms. (Tier 3) Patients with HHT should be screened for cerebral vascular malformations (CVMs). Screening is recommended in the first 6 months of life (or at time of diagnosis), with unenhanced MRI and in an adult patient at age 18 using MRI with and without contrast. Those screening positive should be referred to a center with neurovascular expertise to be considered for invasive testing and individualized management. There is no evidence for any role of repeat MRI screening in adults after an initial negative study. While the rationale for screening for CVMs in HHT is that screening will detect a treatable CAVM before the development of a life-threating or debilitating complications, there no published studies of the efficacy or safety of any form of treatment of CVMs in HHT patients. (Tier 2) No published studies of the efficacy or safety of any form of treatment of CAVMs in HHT patients were identified. This recommendation was based on the effectiveness presented in several large case studies of embolization, microsurgery and stereotactic radiation in patients with non-hht CAVMs. However, more recently in 2014, the results of A Randomised trial of Unruptured Brain Arteriovenous malformations (ARUBA) indicated that individuals who were randomized to medical management alone (pharmacologic therapy for neurologic symptoms as needed) compared to medical management with interventional therapy (surgery, embolization, radiotherapy, alone or in combination) had a significantly decreased risk of death or stroke (hazard ratio 0.27, 95% CI ). This trial included 223 randomized patients with a mean follow-up of 33.3 months. No harms were identified, other than a higher number of strokes (45 vs 12, p<0 0001) and neurological deficits unrelated to stroke (14 vs 1, p=0 0008) in patients allocated to interventional therapy. (Tier 5) Studies of the natural history of cerebral AVMS in patients with HHT are limited. A study of 29 HHT patients with CAVMs found a bleeding risk of 0.4% to 0.7%. A more recent study of 153 HHT patients followed over three years found an overall bleeding rate of 1% per year, with a rupture rate of 0.4% per year for unruptured AVMs and 10% per year for ruptured AVMs. While not specific to HHT patients, the ARUBA study and a recent meta-analysis both found rupture rates of around 2.2% per year for unruptured AVMs. (Tier 5) Patients with HHT should be screened for pulmonary arteriovenous malformations (PAVMs) using transthoracic contrast echocardiography (TTCE). The rationale for screening HHT patients for PAVMs is that screening will detect a treatable PAVM before the development of a life-threatening or debilitating complication. Screening should be performed at the time of initial clinical evaluation to identify patients appropriate for treatment. In patients with negative initial screening, repeat screening should be considered every 5-10 years, within 5 years preceding a planned pregnancy, or after pregnancy. Embolization has been shown in several non-controlled series to be efficacious and have shown high rates of immediate technical success. Longer term, reperfusion did occur in up to 15% of patients and growth of small PAVMs in up to 18%.(Tier 2) (3, 4) (5) 3
4 Family Management Circumstances to Avoid Stage II: Summary Report Patients over 35 should have annual measurements of hemoglobin or hematocrit levels due to the increased risk of GI bleeding with age. Oral and/or intravenous iron supplementation is recommended as first-line therapy for mild anemia and chronic bleeding secondary to HHT-related telangiectasia. There are no studies of iron replacement in HHT. Directed endoscopic evaluation should be undertaken in patients with anemia disproportionate to epistaxis. (Tier 2) Women should be screened and treated as indicated for pulmonary and cerebral AVMs before pregnancy to avoid serious complications. (Tier 3) Individuals with SMAD4 mutations, which are also associated with juvenile polyposis, should undergo gastrointestinal screening for polyposis and gastrointestinal malignancy as per national juvenile polyposis screening recommendations. (Tier 2) [This topic is addressed in a separate report on Juvenile Polyposis Syndrome] If an HHT causing mutation is identified in the index case, diagnostic genetic testing for HHT can be offered to all at risk relatives. (Tier 2) Family members at risk for HHT or in whom HHT has not been ruled out should undergo annual evaluation by a health care provider familiar with HHT, including interval history for epistaxis or other bleeding, shortness of breath or decreased exercise tolerance, and headache or other neurologic symptoms. (Tier 3) Asymptomatic children of a parent with HHT should be considered to have possible HHT unless excluded by genetic testing. If genetic testing is not possible, the clinician should proceed as if the child has HHT and consider appropriate screening for visceral AVMs. (Tier 2) Patients with possible HHT should be screened for CVMs. Screening is recommended in the first 6 months of life (or at time of diagnosis) with an unenhanced MRI and in an adult patient at age 18 using MRI with and without contrast. All patients with a positive MRI should be referred to a center with neurovascular expertise for consideration of invasive testing and further management. (Tier 2) Family members with SMAD4 mutations should undergo gastrointestinal screening for polyposis and gastrointestinal malignancy as per national screening recommendations. (Tier 2) [This topic is addressed in a separate report on Juvenile Polyposis Syndrome] While HHT-related epistaxis is not an absolute contraindication to anticoagulation/antiplatelet therapy, these agents can increase the risk of epistaxis and the decision to use these agents should be based on the individual patient risks and benefits. (Tier 2) Individuals with significant epistaxis are advised to avoid vigorous nose blowing, lifting of heavy objects, straining during bowel movements, and finger manipulation in the nose. (Tier 4) Scuba diving should be avoided unless contrast echocardiography performed within the last five years was negative for evidence of a right to left shunt. (Tier 4) Description of sources of evidence: Tier 1: Evidence from a systematic review, or a meta-analysis or clinical practice guideline clearly based on a systematic review Tier 2: Evidence from clinical practice guidelines or broad-based expert consensus with non-systematic evidence review Tier 3: Evidence from another source with non-systematic review of evidence with primary literature cited Tier 4: Evidence from another source with non-systematic review of evidence with no citations to primary data sources 4
5 Tier 5: Evidence from a non-systematically identified source 5
6 GENE/GENE PANEL: ENG, ACVRL1, SMAD4, GDF2 DISORDER: Hereditary Hemorrhagic Telangiectasia Topic Narrative Description of Evidence Ref 3. What is the chance that this threat will materialize? Mode of Inheritance Prevalence of Genetic Mutations Penetrance OR Relative Risk (include high risk racial or ethnic subgroups) Autosomal dominant Information on the prevalence of HHT-related mutations was unavailable. No evidence was identified on the penetrance of HHT mutations among screen-identified mutation carriers. A French-Italian HHT network examined the frequency of manifestations among 343 patients including 135 probands and 208 relatives with ENG or ACVRL1 mutations (mean age of 50.) Among those with an ENG mutation the frequency of manifestations were: Epistaxis: 97% Telangiectases: 98% Pulmonary AVM: 54% Cerebral AVM: 9% Hepatic AVM: 44% GI bleeding: 7% Among those with an ACVRL1 mutation the frequency of manifestations were: Epistaxis: 89% Telangiectases: 93% Pulmonary AVM: 13% Cerebral AVM: 4% Hepatic AVM: 57.6% GI bleeding: 16.4% (Tier 5) SMAD4: A retrospective review from 5 clinical centers identified 34 SMAD4 mutation carriers from 20 families with a mean age of 35.1 years. Features associated with HHT were documented in 76% of individuals. Epistaxis: 61% Telangiectases: 48% Pulmonary AVM: 53% Cerebral AVM: 4% Hepatic AVM: 38% Colon polyps: 97% (Tier 5) (6) (7) Expressivity Only three HHT patients have been identified with GDF2 mutations. All three individuals had epistaxis and telangiectases. One patient was found to have abnormal liver enyzmes and portal hypertension. The other two patients were not screened for solid organ involvement. (Tier 3) No information on relative risk was identified. Intrafamilial variability is considerable among HHT with signs and symptoms presenting with various severities and at varying ages of onset. (Tier 4) 4. What is the nature of the intervention? Nature of Intervention Identified interventions include various forms of imaging. 5. Would the underlying risk or condition escape detection prior to harm in the (8) 6
7 setting of recommended care? Chance to Escape Clinical Detection Although HHT is a development disorder and infants are occasionally severely affected, in most people the features are age-dependent and the diagnosis is not suspected until adolescence or later. In addition, HHT is often not diagnosed, and entire families therefore remain unaware of available screening and treatment, and children and adults unnecessarily develop stroke or life-threatening hemorrhage. (1, 2) Final Consensus Scores Gene(s) Outcome/intervention pair Severity Likelihood Effectiveness Nature of the Intervention Total Score Anticipatory treatment to avoid CAVM 2 2E 2B 3 9EB ENG morbidity/cerebral MRI Anticipatory treatment to avoid PAVM 2 3E 3B 3 11EB morbidity/ttce Anticipatory treatment to avoid CAVM 2 1E 2B 3 8EB ACVRL1 morbidity/cerebral MRI Anticipatory treatment to avoid PAVM 2 2E 3B 3 10EB morbidity/ttce Anticipatory treatment to avoid CAVM 2 1E 2B 3 8EB SMAD4 morbidity/cerebral MRI Anticipatory treatment to avoid PAVM 2 3E 3B 3 11EB morbidity/ttce Anticipatory treatment to avoid CAVM 2 0D 2B 3 7DB GDF2 morbidity/cerebral MRI Anticipatory treatment to avoid PAVM 2 0D 3B 3 8DB morbidity/ttce To see the scoring key, please go to: Date of Search (MM.DD.YYYY): References 7
8 1. Faughnan ME, Palda VA, Garcia-Tsao G, Geisthoff UW, McDonald J, Proctor DD, et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. Journal of medical genetics. 2011;48: McDonald J, Pyeritz RE. Hereditary Hemorrhagic Telangiectasia. GeneReviews(R) Gupta S, Faughnan ME, Bayoumi AM. Embolization for pulmonary arteriovenous malformation in hereditary hemorrhagic telangiectasia: a decision analysis. Chest. 2009;136(3): Mohr JP, Parides MK, Stapf C, Moquete E, Moy CS, Overbey JR, et al. Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial. Lancet. 2014;383(9917): Brinjikji W, Iyer VN, Sorenson T, Lanzino G. Cerebrovascular Manifestations of Hereditary Hemorrhagic Telangiectasia. Stroke; a journal of cerebral circulation. 2015;46(11): Lesca G, Olivieri C, Burnichon N, Pagella F, Carette MF, Gilbert-Dussardier B, et al. Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: data from the French-Italian HHT network. Genetics in medicine : official journal of the American College of Medical Genetics. 2007;9: Wain KE, Ellingson MS, McDonald J, Gammon A, Roberts M, Pichurin P, et al. Appreciating the broad clinical features of SMAD4 mutation carriers: a multicenter chart review. Genetics in medicine : official journal of the American College of Medical Genetics. 2014;16(8): O'Neill M. TELANGIECTASIA, HEREDITARY HEMORRHAGIC, TYPE 5; HHT5 OMIM2013. Available from: 8
YES NO UNKNOWN. Stage I: Rule-Out Dashboard ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES ( 1 of above)
Stage I: Rule-Out Dashboard GENE/GENE PANEL: SMAD4, BMPR1A DISORDER: Juvenile Polyposis Syndrome HGNC ID: 6670, 1076 OMIM ID: 174900, 175050 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource,
More informationYES NO UNKNOWN PENETRANCE ACTIONABILITY SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES (Proceed to Stage II) YES ( 1 of above)
Stage I: Rule-Out Dashboard GENE/GENE PANEL: ATP7B DISORDER: Wilson Disease HGNC ID: 870 OMIM ID: 277900 ACTIONABILITY 1. Is there a qualifying resource, such as a practice guideline or systematic review,
More informationYES NO UNKNOWN. Stage I: Rule-Out Dashboard Secondary Findings in Adults ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS
Stage I: Rule-Out Dashboard HGNC ID: 6998 OMIM ID: 134610 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource, such as a practice guideline or systematic review, for the genetic condition? 2. Does
More informationACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES ( 1 of above) YES (Proceed to Stage II)
Stage I: Rule-Out Dashboard GENE/GENE PANEL: TNNT2, LMNA HGNC ID: 11949, 6636 ACTIONABILITY 1. Is there a qualifying resource, such as a practice guideline or systematic review, for the genetic condition?
More informationStage I: Rule-Out Dashboard Secondary Findings in Adults
Stage I: Rule-Out Dashboard GENE/GENE PANEL: DNM2 DISORDER: DNM2-Related Intermediate Charcot-Marie-Tooth Neuropathy HGNC ID: 2974 OMIM ID: 606482 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource,
More informationPENETRANCE ACTIONABILITY SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES ( 1 of above) YES (Proceed to Stage II)
Stage I: Binning Dashboard GENE/GENE PANEL: APC ACTIONABILITY 1. Is there a qualifying resource, such as a practice guideline or systematic review, for the genetic condition? 2. Does the practice guideline
More informationHereditary Hemorrhagic Telangiectasia or Osler-Weber -Rendu Syndrome: Management of Epistaxis in 4 Cases.
Hereditary Hemorrhagic Telangiectasia or Osler-Weber -Rendu Syndrome: Management of Epistaxis in 4 Cases. Salina H a, Lim PS a, Gendeh BS a a Department of Otorhinolaringology-Head and Neck Surgery, Faculty
More informationAn Evaluation of the Severity and Progression of Epistaxis in Hereditary Hemorrhagic Telangiectasia 1 Versus Hereditary Hemorrhagic Telangiectasia 2
The Laryngoscope VC 2015 The American Laryngological, Rhinological and Otological Society, Inc. An Evaluation of the Severity and Progression of Epistaxis in Hereditary Hemorrhagic Telangiectasia 1 Versus
More informationStage I: Rule-Out Dashboard
Stage I: Rule-Out Dashboard GENE/GENE PANEL: GLA DISORDER: Fabry disease HGNC ID: 4296 OMIM ID: 301500 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource, such as a practice guideline or systematic
More informationYES NO UNKNOWN. Stage I: Rule-Out Dashboard Secondary Findings in Adults ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS
Stage I: Rule-Out Dashboard HGNC ID: 11949, 6636, 2928 OMIM ID: 191045, 150330, 302045 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource, such as a practice guideline or systematic review, for
More informationNeurologic Manifestation as Initial Presentation in a Case of Hereditary Haemorrhagic Telangiectasia
Clinical Medicine Insights: Case Reports Case report Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Neurologic Manifestation as Initial Presentation in a
More informationStephen Binsse, Jacques Sellier, Jérome Lucas, Mostafa El Hajjam, Pascal Lacombe
SPONTANEOUS RUPTURE OF PULMONARY ARTERIOVENOUS MALFORMATIONS IN HEREDITARY HAEMORRHAGIC TELANGIECTASIA (HHT) REVIEW OF 12 CASES Stephen Binsse, Jacques Sellier, Jérome Lucas, Mostafa El Hajjam, Pascal
More informationStage I: Binning Dashboard
Stage I: Binning Dashboard P[ GENE/GENE PANEL: KCNQ1, KCNH2, SCN5A DISORDER: Romano-Ward Long QT Syndrome HGNC ID: 6294, 6251, 10593 OMIM ID: 192500, 613688, 603830 ACTIONABILITY PENETRANCE 1. Is there
More informationCommon bleeding disorders affecting individuals with Hereditary Hemorrhagic Telangiectasia
TRAINEE SECTION Jennifer LaBranche, BSc 1,2,4 Susan Nahirniak, MD, FRCPC 3 Dilini Vethanayagam, MD, FRCPC 1,4 1University of Alberta - Department of Medicine 2University of Alberta - Department of Biological
More informationCase Report Hereditary Hemorrhagic Telangiectasia with Hepatic Vascular Malformations
Case Reports in Medicine Volume 2015, Article ID 917818, 5 pages http://dx.doi.org/10.1155/2015/917818 Case Report Hereditary Hemorrhagic Telangiectasia with Hepatic Vascular Malformations Yujiro Nishioka,
More informationYES NO UNKNOWN. Stage I: Rule-Out Dashboard Secondary Findings in Adults ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS
Stage I: Rule-Out Dashboard HGNC ID: 9585 OMIM ID: 109400 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource, such as a practice guideline or systematic review, for the genetic condition? 2. Does
More informationMEDICAL NOSEBLEED MANAGEMENT: HEREDITARY HEMORRHAGIC TELANGIECTASIA ASSOCIATED EPISTAXIS COPYRIGHT NOTICE
MEDICAL NOSEBLEED MANAGEMENT: HEREDITARY HEMORRHAGIC TELANGIECTASIA ASSOCIATED EPISTAXIS COPYRIGHT NOTICE Washington University grants permission to use and reproduce the Medical Nosebleed Management:
More informationInternational Journal of Diagnostic Imaging, 2014, Vol. 1, No. 2
CASE REPORT Transthoracic contrast echocardiography for detection of pulmonary arteriovenous malformations in hereditary hemorrhagic telangiectasia: How can the process be improved for patient safety?
More informationThe Usefulness of Capsule Endoscopy
The Usefulness of Capsule Endoscopy David J. Hass, MD, FACG Assistant Clinical Professor of Medicine Yale University School of Medicine Gastroenterology Center of Connecticut Obscure Gastrointestinal Bleeding
More informationPulmonary Arteriovenous Malformations Complicated with Paradoxical Embolic Stroke
Archives of Clinical and Medical Case Reports doi: 10.26502/acmcr.96550032 Volume 2, Issue 4 Case Report Pulmonary Arteriovenous Malformations Complicated with Paradoxical Embolic Stroke Cheah Wai Hun
More informationQuality ID #439: Age Appropriate Screening Colonoscopy National Quality Strategy Domain: Efficiency and Cost Reduction
Quality ID #439: Age Appropriate Screening Colonoscopy National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Efficiency DESCRIPTION:
More informationReproducibility Of Exercise Testing In Patients With Pulmonary Arteriovenous Malformations
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine January 2012 Reproducibility Of Exercise Testing In Patients With
More informationPENETRANCE ACTIONABILITY SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES (Proceed to Stage II) YES ( 1 of above)
Stage I: Rule-Out Dashboard GENE/GENE PANEL: TSC1, TSC2 DISORDER: Tuberous Sclerosis Complex (TSC) HGNC ID: 12362, 12363 OMIM ID: 191100, 613254 ACTIONABILITY 1. Is there a qualifying resource, such as
More informationRole of Transthoracic Contrast Echocardiography in the Clinical Diagnosis of Hereditary Hemorrhagic Telangiectasia
CHEST Original Research PULMONARY PROCEDURES Role of Transthoracic Contrast Echocardiography in the Clinical Diagnosis of Hereditary Hemorrhagic Telangiectasia Sebastiaan Velthuis, MD ; Veronique M. M.
More information24. An infant with recurrent pneumonia underwent a frontal chest radiograph (Fig 24-A) followed by
24. An infant with recurrent pneumonia underwent a frontal chest radiograph (Fig 24-A) followed by diagnosis? ndings, what is the most likely A. Pulmonary sequestration B. Congenital pulmonary airway malformation
More information27
26 27 28 29 30 31 32 33 34 35 Diagnosis:? Diagnosis: Juvenile Polyposis with BMPR1A Mutation 36 Juvenile Polyposis Syndrome Rare Autosomal Dominant Disorder with Multiple Juvenile Polyps in GI Tract Juvenile
More informationYES NO UNKNOWN. Stage I: Rule-Out Dashboard Secondary Findings in Adults ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS
Stage I: Rule-Out Dashboard GENE/GENE PANEL: LMNA, EMD, FHL1 DISORDER: Emery-Dreifuss Muscular Dystrophy (AD, XL) HGNC ID: 6636, 3331, 3702 OMIM ID: 181350, 310300, 300696 ACTIONABILITY PENETRANCE 1. Is
More informationUpdated Ischemic Stroke Guidelines นพ.ส ชาต หาญไชยพ บ ลย ก ล นายแพทย ทรงค ณว ฒ สาขาประสาทว ทยา สถาบ นประสาทว ทยา กรมการแพทย กระทรวงสาธารณส ข
Updated Ischemic Stroke Guidelines นพ.ส ชาต หาญไชยพ บ ลย ก ล นายแพทย ทรงค ณว ฒ สาขาประสาทว ทยา สถาบ นประสาทว ทยา กรมการแพทย กระทรวงสาธารณส ข Emergency start at community level: Prehospital care Acute stroke
More informationYES NO UNKNOWN. Stage I: Rule-Out Dashboard Secondary Findings in Adults ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS
Stage I: Rule-Out Dashboard GENE/GENE PANEL: TTR DISORDER: Hereditary transthyretin-related amyloidosis HGNC ID: 12405 OMIM ID: 105210 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource, such as
More informationBrain Abscess as a Manifestation of Hereditary Hemorrhagic Telangiectasia in a Pediatric Patient
Brain Abscess as a Manifestation of Hereditary Hemorrhagic Telangiectasia in a Pediatric Patient Jose M. Soto, BS¹; Tibisay Villalobos, MD² ¹University of South Florida College of Medicine, Tampa, FL ²Children
More informationRendu Osler Weber disease or Hereditary Hemorrhagic Telangiectasia (HHT): liver vascular involvement
Rendu Osler Weber disease or Hereditary Hemorrhagic Telangiectasia (HHT): liver vascular involvement Elisabetta Buscarini Gastroenterology Dept European Reference Center for HHT ASST Ospedale Maggiore
More informationAnatomy, Physiology and Management of Patients with Diffuse Pulmonary Arteriovenous Malformations
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 4-12-2009 Anatomy, Physiology and Management of Patients with Diffuse
More informationGenotype phenotype relationship in Hereditary Hemorrhagic Telangiectasia
JMG Online First, published on September 9, 2005 as 10.1136/jmg.2005.035451 Genotype phenotype relationship in Hereditary Hemorrhagic Telangiectasia T.G.W. Letteboer 1, J.J. Mager 2, R.J. Snijder 2, B.P.C.
More informationGUIDELINES FOR THE EARLY MANAGEMENT OF PATIENTS WITH ACUTE ISCHEMIC STROKE
2018 UPDATE QUICK SHEET 2018 American Heart Association GUIDELINES FOR THE EARLY MANAGEMENT OF PATIENTS WITH ACUTE ISCHEMIC STROKE A Summary for Healthcare Professionals from the American Heart Association/American
More informationLife after ARUBA: Management of Unruptured Brain Arteriovenous Malformations (AVMs)
Life after ARUBA: Management of Unruptured Brain Arteriovenous Malformations (AVMs) Eric L. Zager, MD University of Pennsylvania Department of Neurosurgery No Disclosures Brain AVMs Incidence ~1 in 100,000
More informationCerebral abscesses among Danish patients with hereditary haemorrhagic telangiectasia
Acta Neurol Scand 2014: 129: 192 197 DOI: 10.1111/ane.12167 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd ACTA NEUROLOGICA SCANDINAVICA Cerebral abscesses among Danish patients with hereditary
More informationYou Won t Believe What I Saw on. Disclosures. Goals. Dimensions 2013 October 18 th Michael Pfeiffer, MD. No Financial Disclosures
You Won t Believe What I Saw on that ECHO! Dimensions 2013 October 18 th Michael Pfeiffer, MD Disclosures No Financial Disclosures Goals Review unusual and unique echocardiographic images. Briefly present
More informationGERIATRICS CASE PRESENTATION
GERIATRICS CASE PRESENTATION CASE 79 year old Patient X was admitted to hospital with SOB. He had a hx of sarcoidosis and asbestosis. Home oxygen requirement is 3-3.5litre. He was admitted, given ceftriaxone
More informationVascular Malformations of the Brain: A Review of Imaging Features and Risks
Vascular Malformations of the Brain: A Review of Imaging Features and Risks Comprehensive Neuroradiology: Best Practices October 27-30, 2016 Sudhakar R. Satti, MD Associate Director Neurointerventional
More informationCost savings through molecular diagnosis for hereditary hemorrhagic telangiectasia
American College of Medical Genetics and Genomics Cost savings through molecular diagnosis for hereditary hemorrhagic telangiectasia Barbara A. Bernhardt, MS, CGC 1 3, Cara Zayac, BS 1,2, Scott O. Trerotola,
More informationVascular Malformations of the Brain. William A. Cox, M.D. Forensic Pathologist/Neuropathologist. September 8, 2014
Vascular Malformations of the Brain William A. Cox, M.D. Forensic Pathologist/Neuropathologist September 8, 2014 Vascular malformations of the brain are classified into four principal groups: arteriovenous
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Blum CA, Nigro N, Briel M, et al. Adjunct prednisone
More informationEndovascular Treatment of Cerebral Arteriovenous Malformations. Bs. Nguyễn Ngọc Pi Doanh- Bs Đặng Ngọc Dũng Khoa Ngoại Thần Kinh
Endovascular Treatment of Cerebral Arteriovenous Malformations Bs. Nguyễn Ngọc Pi Doanh- Bs Đặng Ngọc Dũng Khoa Ngoại Thần Kinh Stroke Vascular Malformations of the Brain Epidemiology: - Incidence: 0.1%,
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.16 Subject: Letairis Page: 1 of 6 Last Review Date: June 24, 2016 Letairis Description Letairis (ambrisentan)
More informationA Case Report of Hereditary Hemorrhagic Telangiectasia (HHT)
Case report A Case Report of Hereditary Hemorrhagic Telangiectasia (HHT) Martín Alonso Gómez, MD 1, Oscar Fernando Ruiz, MD 2, William Otero, MD 3 1 Associate Professor Gastroenterology, Faculty of Medicine
More informationHereditary hemorrhagic telangiectasia (HHT): Whole body imaging findings with emphasis in central nervous system involvement
Hereditary hemorrhagic telangiectasia (HHT): Whole body imaging findings with emphasis in central nervous system involvement Poster No.: C-824 Congress: ECR 2009 Type: Topic: Authors: Keywords: DOI: Educational
More informationCLINICAL FOCUS. Juvenile Polyposis. Winter 2009
CLINICAL FOCUS Juvenile Polyposis Carol Durno, MD, MSc Registry Pediatric Gastroenterologist People can have many polyps in the gastrointestinal tract. The type and number of polyps found help determine
More informationAlliance A Symptomatic brain radionecrosis after receiving radiosurgery for
RANDOMIZED PHASE II STUDY: CORTICOSTEROIDS + BEVACIZUMAB VS. CORTICOSTEROIDS + PLACEBO (BEST) FOR RADIONECROSIS AFTER RADIOSURGERY FOR BRAIN METASTASES Pre-registration Eligibility Criteria Required Initial
More informationIn Press at Blood Reviews, July 2010 Abstract. Hereditary haemorrhagic telangiectasia, inherited as an autosomal dominant trait, affects
In Press at Blood Reviews, July 2010 Abstract Hereditary haemorrhagic telangiectasia, inherited as an autosomal dominant trait, affects Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis
More informationWhat Is an Arteriovenous malformation (AVM)?
American Society of Neuroradiology What Is an Arteriovenous malformation (AVM)? From the Cerebrovascular Imaging and Intervention Committee of the American Heart Association Cardiovascular Council Randall
More informationACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis
ACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis Guadalupe Garcia-Tsao, M.D., 1 Arun J. Sanyal, M.D., 2 Norman D. Grace,
More informationDistinct Forms of Pulmonary Hypertension Complicate Hereditary Hemorrhagic Telangiectasia
Distinct Forms of Pulmonary Hypertension Complicate Hereditary Hemorrhagic Telangiectasia John T. Battaile, MD Department of Medicine Division of Pulmonary and Critical Care University of Texas Southwestern
More informationExplaining All of the Options for AVM: Cerebral Arteriovenous Malformation
Explaining All of the Options for AVM: Cerebral Arteriovenous Malformation Recorded on: November 19, 2012 Bernard Bendok, M.D. Director of the Neurointerventional Program Northwestern Memorial Hospital
More informationComorbidity among HHT patients and their controls in a 20 years follow-up period
Aagaard et al. Orphanet Journal of Rare Diseases (2018) 13:223 https://doi.org/10.1186/s13023-018-0962-8 RESEARCH Open Access Comorbidity among HHT patients and their controls in a 20 years follow-up period
More informationWASHINGTON UNIVERSITY SCHOOL OF MEDICINE. Cranial Health History Form
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE Cranial Health History Form Welcome to the Neurosurgery Department at Washington University. To help us treat you, please fill this form out completely. Your Name:
More informationNeurosurgical decision making in structural lesions causing stroke. Dr Rakesh Ranjan MS, MCh, Dip NB (Neurosurgery)
Neurosurgical decision making in structural lesions causing stroke Dr Rakesh Ranjan MS, MCh, Dip NB (Neurosurgery) Subarachnoid Hemorrhage Every year, an estimated 30,000 people in the United States experience
More informationMarc Norman, Ph.D. - Do Not Use without Permission 1. Cerebrovascular Accidents. Marc Norman, Ph.D. Department of Psychiatry
Cerebrovascular Accidents Marc Norman, Ph.D. Department of Psychiatry Neuropsychiatry and Behavioral Medicine Neuropsychology Clinical Training Seminar 1 5 http://www.nlm.nih.gov/medlineplus/ency/images/ency/fullsize/18009.jpg
More informationMichele Bettinelli RN Maria Scholz RN Sandra Scolaro RN
Michele Bettinelli RN Maria Scholz RN Sandra Scolaro RN Objectives Define Peutz-Jeghers Syndrome (PJS) Describe the management and treatment of PJS Discuss the patient experience associated with the diagnosis
More informationPre-Hospital Stroke Care: Bringing It To The Street. by Bob Atkins, NREMT-Paramedic AEMD EMS Director Bedford Regional Medical Center
Pre-Hospital Stroke Care: Bringing It To The Street by Bob Atkins, NREMT-Paramedic AEMD EMS Director Bedford Regional Medical Center Overview/Objectives Explain the reasons or rational behind the importance
More informationFamilial Adenomatous Polyposis
Familial Adenomatous Polyposis 1 in 10,000 incidence 100 s to 1000 s of colonic adenomas by teens Cancer risk: colon, gastric, duodenum (periampulla), small bowel, pancreas, papillary thyroid, childhood
More informationPulmonary Arteriovenous Malformations And Osler Weber Rendu Syndrome: An Unusual Cause Of Dyspnea
ISPUB.COM The Internet Journal of Pulmonary Medicine Volume 5 Number 2 Pulmonary Arteriovenous Malformations And Osler Weber Rendu Syndrome: An Unusual Cause Of H Amin, A Friere, C Lal, M Pugazhenthi Citation
More informationDiagnosis and Management of AVM in the Pregnant Patient
Diagnosis and Management of AVM in the Pregnant Patient Wade Cooper, D.O. University of Michigan Assistant Professor Departments of Neurology & Anesthesiology Disclosures Wade Cooper - None Developmental
More informationJournal Club. 1. Develop a PICO (Population, Intervention, Comparison, Outcome) question for this study
Journal Club Articles for Discussion Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-pa Stroke Study Group. N Engl J Med. 1995 Dec
More informationContents. Version 1.0: 01/02/2010 Protocol# ISRCTN Page 1 of 7
Contents 1. INTRODUCTION... 2 2. STUDY SYNOPSIS... 2 3. STUDY OBJECTIVES... 2 3.1. Primary Objective... 2 3.2. Secondary Objectives... 2 3.3. Assessment of Objectives... 3 3.4. Change the Primary Objective
More informationVisceral aneurysm. Diagnosis and Interventions M.NEDEVSKA
Visceral aneurysm Diagnosis and Interventions M.NEDEVSKA History 1953 De Bakeyand Cooley Visceral aneurysm VAAs rare, reported incidence of 0.01 to 0.2% on routine autopsies. Clinically important Potentially
More informationGI Polyp syndromes in children. Screening and surveillance, surgery.
Dr Warren Hyer Consultant Paediatric Gastroenterologist St Mark s Hospital, UK GI Polyp syndromes in children Screening and surveillance, surgery. No conflict of interests to declare Objectives Understand
More informationVascular Ehlers- Danlos in the pediatric population
Vascular Ehlers- Danlos in the pediatric population Shaine A. Morris, MD, MPH Pediatric Cardiology Texas Children s Hospital, Baylor College of Medicine Objectives Learn what Vascular EDS is, and how it
More informationImaging abdominal vascular emergencies. V.Stoynova
Imaging abdominal vascular emergencies V.Stoynova Abdominal vessels V. Stoynova 2 Acute liver bleeding trauma anticoagulant therapy liver disease : HCC, adenoma, meta, FNH, Hemangioma Diagnosis :CT angiography
More informationCase Report A novel germline mutation in SMAD4 gene in a hereditary hemorrhagic telangiectasia family
Int J Clin Exp Med 2017;10(6):9649-9653 www.ijcem.com /ISSN:1940-5901/IJCEM0043096 Case Report A novel germline mutation in SMAD4 gene in a hereditary hemorrhagic telangiectasia family Changning Hao *,
More informationTo provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
ACETYL SALICYLIC ACID TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
More informationPrecision Medicine and Genetic Counseling : Is Yes always the correct answer?
Precision Medicine and Genetic Counseling : Is Yes always the correct answer? Beverly M. Yashar, MS, PhD, CGC Director, Graduate Program in Genetic Counseling Professor, Department of Human Genetics. (yashar@umich.edu)
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Tracleer Page: 1 of 6 Last Review Date: September 15, 2017 Tracleer Description Tracleer (bosentan)
More informationDurlaza. Durlaza (aspirin) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.13 Subject: Durlaza Page: 1 of 4 Last Review Date: September 15, 2016 Durlaza Description Durlaza
More informationResult Navigator. Positive Test Result: BMPR1A. After a positive test result, there can be many questions about what to do next. Navigate Your Results
Result Navigator Positive Test Result: BMPR1A Positive test results identify a change, or misspelling, of DNA that is known or predicted to cause an increased risk for cancer. DNA is the blueprint of life
More informationa. Ischemic stroke An acute focal infarction of the brain or retina (and does not include anterior ischemic optic neuropathy (AION)).
12.0 Outcomes 12.1 Definitions 12.1.1 Neurologic Outcome Events a. Ischemic stroke An acute focal infarction of the brain or retina (and does not include anterior ischemic optic neuropathy (AION)). Criteria:
More informationPulmonary arteriovenous malformations (PAVMs)
Endovascular Repair of PAVM by Embolotherapy In a patient with a transient ischemic attack or stroke, a positive contrast echocardiogram does not always mean a patent foramen ovale. BY ROBERT I. WHITE,
More informationYES NO UNKNOWN. Stage I: Rule-Out Dashboard Secondary Findings in Adults ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS
Stage I: Rule-Out Dashboard GENE/GENE PANEL: COL5A1, COL5A2 DISORDER: Ehlers-Danlos Syndrome, Classic Type HGNC ID: 2209, 2210 OMIM ID: 130000 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource,
More informationAn Epistaxis Severity Score for Hereditary Hemorrhagic Telangiectasia
The Laryngoscope VC 2010 The American Laryngological, Rhinological and Otological Society, Inc. An Epistaxis Severity Score for Hereditary Hemorrhagic Telangiectasia Jeffrey B. Hoag, MD, MS; Peter Terry,
More informationHydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease
Hydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease A Pocket Guide for the Clinician Susan E. Creary, MD, MSc 1 John J. Strouse, MD, PhD 2 1 The Ohio State University School of
More informationA guide to understanding variant classification
White paper A guide to understanding variant classification In a diagnostic setting, variant classification forms the basis for clinical judgment, making proper classification of variants critical to your
More informationBEVACIZUMAB in Ovarian cancer. Cancer drug fund application and approval is required for funding. Continue Bevacizumab treatment for up to 18 cycles.
BEVACIZUMAB in Ovarian cancer Page 1 of 5 Indication: First line treatment in advanced (Stage IIIc/IV) ovarian cancer, either sub-optimally debulked at primary or delayed primary surgery, or not suitable
More informationVessel malformation vascular malformation vascular malformation vascular malformation Vascular malformation vascular malformations
A vascular malformation is another type of birthmark, or congenital (present at birth) growth, made up of arteries, veins, capillaries, or lymphatic vessels. There are several different types of malformations
More informationGI EMERGENCIES Acute Abdominal Pain
GI EMERGENCIES Acute Abdominal Pain Marcia Cruz-Correa, MD, PhD, AGAF. FASGE Associate Professor of Medicine, Biochemistry, Surgery Director Translational Research University of Puerto Rico Comprehensive
More informationSupplement Table 1. Definitions for Causes of Death
Supplement Table 1. Definitions for Causes of Death 3. Cause of Death: To record the primary cause of death. Record only one answer. Classify cause of death as one of the following: 3.1 Cardiac: Death
More informationTHE FRAMINGHAM STUDY Protocol for data set vr_soe_2009_m_0522 CRITERIA FOR EVENTS. 1. Cardiovascular Disease
THE FRAMINGHAM STUDY Protocol for data set vr_soe_2009_m_0522 CRITERIA FOR EVENTS 1. Cardiovascular Disease Cardiovascular disease is considered to have developed if there was a definite manifestation
More information9/10/2012. Chapter 44. Learning Objectives. Learning Objectives (Cont d) Bleeding
Chapter 44 Bleeding 1 Learning Objectives Describe the etiology, history, and physical findings of external bleeding Predict hemorrhage on the basis of the patient s mechanism of injury Distinguish between
More informationWhat s New in Newborn Screening?
What s New in Newborn Screening? Funded by: Illinois Department of Public Health Information on Newborn Screening Newborn screening in Illinois is administered by the Illinois Department of Public Health.
More informationThrombosis and emboli. Peter Nagy
Thrombosis and emboli Peter Nagy A thrombus is any solid object developing from the blood in vivo within the vascular system or heart. Thrombosis is hemostasis in the wrong place. Major components, forms:
More informationPatient Name Date of Birth Age. Other phone ( ) . Other
GASTROINTESTINAL & MINIMALLY INVASIVE SURGERY HEALTH HISTORY QUESTIONNAIRE Date Patient Name _ Date of Birth Age Daytime phone ( ) Other phone ( ) Email How did you hear about us? My doctor Yellow pages
More informationImpact of Pulmonary Arteriovenous Malformations on Respiratory Related Quality of Life in Patients with Hereditary Haemorrhagic Telangiectasia
Impact of Pulmonary Arteriovenous Malformations on Respiratory Related Quality of Life in Patients with Hereditary Haemorrhagic Telangiectasia Sandra Blivet 1, Daniel Cobarzan 1, Alain Beauchet 2, Mostafa
More informationOnline Supplementary Data. Country Number of centers Number of patients randomized
A Randomized, Double-Blind, -Controlled, Phase-2B Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients with Sepsis and Suspected Disseminated Intravascular
More informationUltrasound-enhanced, catheter-directed thrombolysis for pulmonary embolism
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Ultrasound-enhanced, catheter-directed thrombolysis for pulmonary embolism A pulmonary embolism (PE) is
More informationName: Bashair Hashim Ali Age:46 years Residence: Mosul/ Al-Samah Q. Occupation: non-employee. Date of admission: Date of exam:
Name: Bashair Hashim Ali Age:46 years Residence: Mosul/ Al-Samah Q. Occupation: non-employee. Date of admission: 17-8-2013 Date of exam: 17-8-2013 Chief complaint: passing of black coloured stool for few
More informationWiskott-Aldrich Registry Data Collection Form Patient Identification: Patient Name (first, middle, last)
Patient Identification: Patient Name (first, middle, last) Patient s USIDNET Registry Number assigned after online enrollment Date of Birth / / (mm/dd/yyyy) or Year of Birth Gender: male [ ], female [
More informationSupratentorial cerebral arteriovenous malformations : a clinical analysis
Original article: Supratentorial cerebral arteriovenous malformations : a clinical analysis Dr. Rajneesh Gour 1, Dr. S. N. Ghosh 2, Dr. Sumit Deb 3 1Dept.Of Surgery,Chirayu Medical College & Research Centre,
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.21 Subject: Orenitram Page: 1 of 6 Last Review Date: June 24, 2016 Orenitram Description Orenitram
More informationNosebleed (Epistaxis)
2015 WebMD, LLC. All rights reserved. Nosebleed (Epistaxis) Nosebleed Overview Nosebleed Causes Nosebleeds in Children Nosebleed Symptoms When to Seek Medical Care Nosebleed Diagnosis Nosebleed Self-Care
More informationEPISTAXIS. Nasal Trauma, and other emergencies. Marc A. Tewfik MDCM, MSc, FRCSC
EPISTAXIS Nasal Trauma, and other emergencies Marc A. Tewfik MDCM, MSc, FRCSC Assistant Professor, McGill University Otolaryngology-Head & Neck Surgery DISCLOSURES Speaker/Consultant Merck Novartis MEDA
More informationADCIRCA (tadalafil) The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Pulmonary arterial hypertension is a rare disorder of the pulmonary arteries in which the pulmonary arterial pressure rises above normal levels in the absence
More information